Brokerages Set Prestige Consumer Healthcare Inc. (NYSE:PBH) Price Target at $80.60

Prestige Consumer Healthcare Inc. (NYSE:PBH) has been assigned an average rating of “Hold” from the seven research firms that are covering the firm, Marketbeat reports. Four research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $80.60.

PBH has been the topic of a number of recent research reports. Zacks Research upgraded Prestige Consumer Healthcare from a “strong sell” rating to a “hold” rating in a research note on Monday, November 10th. Jefferies Financial Group reduced their price target on Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating for the company in a report on Friday, January 30th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research note on Thursday, January 22nd.

Insiders Place Their Bets

In other Prestige Consumer Healthcare news, VP Jeffrey Zerillo sold 1,000 shares of Prestige Consumer Healthcare stock in a transaction that occurred on Wednesday, February 11th. The shares were sold at an average price of $65.93, for a total value of $65,930.00. Following the completion of the sale, the vice president directly owned 41,048 shares in the company, valued at $2,706,294.64. The trade was a 2.38% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 1.40% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Bank of Montreal Can lifted its stake in shares of Prestige Consumer Healthcare by 2.0% in the 2nd quarter. Bank of Montreal Can now owns 9,351 shares of the company’s stock valued at $747,000 after purchasing an additional 182 shares during the last quarter. Lido Advisors LLC boosted its holdings in Prestige Consumer Healthcare by 5.4% in the fourth quarter. Lido Advisors LLC now owns 3,778 shares of the company’s stock worth $235,000 after purchasing an additional 192 shares in the last quarter. Profund Advisors LLC increased its position in Prestige Consumer Healthcare by 3.2% during the third quarter. Profund Advisors LLC now owns 6,770 shares of the company’s stock worth $422,000 after buying an additional 207 shares during the last quarter. Cerity Partners LLC increased its position in Prestige Consumer Healthcare by 5.9% during the second quarter. Cerity Partners LLC now owns 3,884 shares of the company’s stock worth $310,000 after buying an additional 218 shares during the last quarter. Finally, UMB Bank n.a. raised its holdings in Prestige Consumer Healthcare by 110.1% during the fourth quarter. UMB Bank n.a. now owns 418 shares of the company’s stock valued at $26,000 after buying an additional 219 shares in the last quarter. Institutional investors and hedge funds own 99.95% of the company’s stock.

Prestige Consumer Healthcare Trading Down 1.1%

Shares of NYSE:PBH opened at $67.20 on Wednesday. The firm has a fifty day moving average of $65.85 and a two-hundred day moving average of $63.57. The firm has a market capitalization of $3.18 billion, a P/E ratio of 17.78, a price-to-earnings-growth ratio of 2.11 and a beta of 0.41. Prestige Consumer Healthcare has a 12-month low of $57.25 and a 12-month high of $90.04. The company has a quick ratio of 1.93, a current ratio of 3.11 and a debt-to-equity ratio of 0.58.

Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings results on Thursday, February 5th. The company reported $1.14 EPS for the quarter, missing the consensus estimate of $1.16 by ($0.02). Prestige Consumer Healthcare had a net margin of 16.90% and a return on equity of 12.02%. The company had revenue of $283.44 million for the quarter, compared to analysts’ expectations of $286.93 million. During the same quarter in the prior year, the firm earned $1.22 earnings per share. The company’s revenue was down 2.4% on a year-over-year basis. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.540 EPS. On average, equities analysts expect that Prestige Consumer Healthcare will post 4.5 EPS for the current fiscal year.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).